Tempest Therapeutics (TPST) Competitors $0.92 -0.03 (-3.17%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.92 +0.01 (+0.77%) As of 01/31/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TPST vs. NBTX, FATE, KYTX, BMEA, TIL, IPHA, FTLF, ADAP, ARTV, and PBYIShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Nanobiotix (NBTX), Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Biomea Fusion (BMEA), Instil Bio (TIL), Innate Pharma (IPHA), FitLife Brands (FTLF), Adaptimmune Therapeutics (ADAP), Artiva Biotherapeutics (ARTV), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. Nanobiotix Fate Therapeutics Kyverna Therapeutics Biomea Fusion Instil Bio Innate Pharma FitLife Brands Adaptimmune Therapeutics Artiva Biotherapeutics Puma Biotechnology Tempest Therapeutics (NASDAQ:TPST) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends. Which has more volatility and risk, TPST or NBTX? Tempest Therapeutics has a beta of -1.69, indicating that its stock price is 269% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Do insiders & institutionals have more ownership in TPST or NBTX? 22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 4.7% of Tempest Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor TPST or NBTX? In the previous week, Nanobiotix had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Nanobiotix and 3 mentions for Tempest Therapeutics. Nanobiotix's average media sentiment score of 1.19 beat Tempest Therapeutics' score of 0.63 indicating that Nanobiotix is being referred to more favorably in the news media. Company Overall Sentiment Tempest Therapeutics Positive Nanobiotix Positive Do analysts rate TPST or NBTX? Tempest Therapeutics currently has a consensus target price of $20.00, indicating a potential upside of 2,085.79%. Nanobiotix has a consensus target price of $12.00, indicating a potential upside of 243.35%. Given Tempest Therapeutics' higher possible upside, research analysts clearly believe Tempest Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Nanobiotix 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TPST or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -187.44% -82.61% Nanobiotix N/A N/A N/A Which has better valuation & earnings, TPST or NBTX? Tempest Therapeutics has higher earnings, but lower revenue than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$29.49M-$1.53-0.60Nanobiotix$39.18M4.20-$42.97MN/AN/A Does the MarketBeat Community favor TPST or NBTX? Tempest Therapeutics received 89 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 65.79% of users gave Tempest Therapeutics an outperform vote while only 64.71% of users gave Nanobiotix an outperform vote. CompanyUnderperformOutperformTempest TherapeuticsOutperform Votes10065.79% Underperform Votes5234.21% NanobiotixOutperform Votes1164.71% Underperform Votes635.29% SummaryNanobiotix beats Tempest Therapeutics on 7 of the 13 factors compared between the two stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.15M$6.88B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E RatioN/A4.5158.9914.21Price / SalesN/A320.231,258.0383.19Price / CashN/A73.5045.9637.70Price / Book0.665.275.124.71Net Income-$29.49M$136.98M$111.17M$224.24M7 Day Performance-3.69%-0.59%2.37%-0.17%1 Month Performance9.65%0.18%3.19%0.60%1 Year Performance-77.52%7.68%24.69%20.43% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics2.4397 of 5 stars$0.92-3.2%$20.00+2,085.8%-75.9%$39.15MN/A-0.6020Short Interest ↓NBTXNanobiotix3.2067 of 5 stars$3.38-2.2%$12.00+255.6%-54.0%$159.06M$39.18M0.00100Short Interest ↓FATEFate Therapeutics4.1868 of 5 stars$1.38+3.4%$6.75+390.9%-78.9%$156.60M$63.53M-0.83550Short Interest ↓Positive NewsGap DownKYTXKyverna Therapeutics1.7557 of 5 stars$3.55-1.4%$25.71+624.1%N/A$153.69M$7.03M0.0096Short Interest ↑BMEABiomea Fusion2.8283 of 5 stars$4.20-4.8%$39.36+837.2%-76.9%$152.17MN/A-1.0550Short Interest ↑TILInstil Bio3.1012 of 5 stars$23.23-0.9%$114.00+390.7%+88.6%$151.69MN/A-2.01410Short Interest ↑IPHAInnate Pharma2.9813 of 5 stars$1.76-0.8%$11.50+555.3%-31.7%$147.12M$66.71M0.00220Short Interest ↓Gap UpHigh Trading VolumeFTLFFitLife Brands4.6728 of 5 stars$31.97+1.0%$40.00+25.1%+38.2%$147.08M$52.70M18.9220Short Interest ↓News CoverageADAPAdaptimmune Therapeutics2.428 of 5 stars$0.57-3.4%$2.79+387.3%-38.5%$146.62M$60.28M-2.60490Short Interest ↑News CoverageARTVArtiva BiotherapeuticsN/A$6.01+1.3%$21.00+249.7%N/A$145.86MN/A0.0081Gap UpPBYIPuma Biotechnology4.2674 of 5 stars$2.95-0.5%$7.00+137.7%-38.5%$144.57M$235.60M6.14200Positive News Related Companies and Tools Related Companies NBTX Alternatives FATE Alternatives KYTX Alternatives BMEA Alternatives TIL Alternatives IPHA Alternatives FTLF Alternatives ADAP Alternatives ARTV Alternatives PBYI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TPST) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
